Chronic Kidney Disease-Mineral and Bone Disorder in Asia

Overview

Journal Kidney Dis (Basel)

Specialty Nephrology

Date 2017 Aug 9

PMID 28785558

Citations 2

Authors

Masafumi Fukagawa

Hirotaka Komaba

Affiliations

Soon will be listed here.

Abstract

Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the most common complications in patients with CKD. As CKD-MBD is a systemic syndrome, prevention and management should be aimed at achieving better survival and less risk of cardiovascular events and fractures.

Summary: Although target ranges for serum markers of mineral metabolism have been proposed in several global or local guidelines, these were mostly based on data from non-Asian patients. Additionally, there remain differences in medical and social systems as well as in economic status, even among Asian countries and areas.

Key Message: Asian CKD patient data needs to be analyzed, published, and shared to establish optimal local strategies for CKD-MBD management.

Citing Articles

Carotid intima-media thickness, fibroblast growth factor 23, and mineral bone disorder in children with chronic kidney disease.

Palupi-Baroto R, Hermawan K, Murni I, Nurlita T, Prihastuti Y, Puspitawati I BMC Nephrol. 2024; 25(1):369.

PMID: 39433982 PMC: 11494757. DOI: 10.1186/s12882-024-03771-z.

Mineral bone disorder in children with chronic kidney disease: Data from the KNOW-Ped CKD (Korean cohort study for outcome in patients with pediatric chronic kidney disease) study.

Jung J, Lee K, Park E, Park Y, Kang H, Ahn Y Front Pediatr. 2023; 11:994979.

PMID: 36873652 PMC: 9982157. DOI: 10.3389/fped.2023.994979.

References

Scialla J, Xie H, Rahman M, Anderson A, Isakova T, Ojo A . Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2013; 25(2):349-60. PMC: 3904568. DOI: 10.1681/ASN.2013050465. View

Yokoyama K, Kurita N, Fukuma S, Akizawa T, Fukagawa M, Onishi Y . Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy. Nephrol Dial Transplant. 2016; 32(3):534-541. PMC: 5837642. DOI: 10.1093/ndt/gfw020. View

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

Kuro-O M . The FGF23 and Klotho system beyond mineral metabolism. Clin Exp Nephrol. 2016; 21(Suppl 1):64-69. DOI: 10.1007/s10157-016-1357-6. View

Goto S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Nishioka M . Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol. 2011; 6(6):1375-84. PMC: 3109935. DOI: 10.2215/CJN.08841010. View

Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T . Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis. 2012; 60(2):262-71. DOI: 10.1053/j.ajkd.2011.12.034. View

Fujii H, Joki N . Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol. 2017; 21(Suppl 1):53-63. DOI: 10.1007/s10157-016-1363-8. View

. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI: 10.1038/ki.2009.188. View

Hamano T, Sakaguchi Y, Fujii N, Isaka Y . Clinical features of CKD-MBD in Japan: cohort studies and registry. Clin Exp Nephrol. 2016; 21(Suppl 1):9-20. DOI: 10.1007/s10157-016-1367-4. View

10.

LAWSON D, Fraser D, KODICEK E, Morris H, Williams D . Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature. 1971; 230(5291):228-30. DOI: 10.1038/230228a0. View

11.

Leung C, Cheung W, Li P . Renal registry in Hong Kong-the first 20 years. Kidney Int Suppl (2011). 2015; 5(1):33-38. PMC: 4455190. DOI: 10.1038/kisup.2015.7. View

12.

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S . Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012; 7(5):810-9. DOI: 10.2215/CJN.08680811. View

13.

Hwang E, Choi B, Oh K, Kwon Y, Kim G . Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations. Kidney Res Clin Pract. 2015; 34(1):4-12. PMC: 4570602. DOI: 10.1016/j.krcp.2015.02.002. View

14.

Danese M, Belozeroff V, Smirnakis K, Rothman K . Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3(5):1423-9. PMC: 2518803. DOI: 10.2215/CJN.01060308. View

15.

London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18(9):1731-40. DOI: 10.1093/ndt/gfg414. View

16.

Fukagawa M, Hamada Y, Nakanishi S, Tanaka M . The kidney and bone metabolism: Nephrologists' point of view. J Bone Miner Metab. 2006; 24(6):434-8. DOI: 10.1007/s00774-006-0719-7. View

17.

Ketteler M, Elder G, Evenepoel P, Ix J, Jamal S, Lafage-Proust M . Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2015; 87(3):502-28. DOI: 10.1038/ki.2014.425. View

18.

Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M . Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2007; 23(1):328-35. DOI: 10.1093/ndt/gfm534. View

19.

Komaba H, Fukagawa M . Phosphate-a poison for humans?. Kidney Int. 2016; 90(4):753-63. DOI: 10.1016/j.kint.2016.03.039. View

20.

Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T . A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese.... Nephrol Dial Transplant. 2017; 32(10):1723-1730. PMC: 5837215. DOI: 10.1093/ndt/gfw408. View